Knikord
19/04/22 07:45
Ha respondido al tema Novavax (NVAX): Un Nuevo Comienzo
Ir a respuesta
Takeda (TSE:4502/NYSE:TAK) today announced that it has received manufacturing and marketing approval from the Japan Ministry of Health, Labour and Welfare (MHLW) for Nuvaxovid® Intramuscular Injection (Nuvaxovid), a novel recombinant protein-based COVID-19 vaccine, for primary and booster immunization in individuals aged 18 and older. Nuvaxovid Intramuscular Injection, containing Matrix-MTM adjuvant, is the first recombinant protein-based COVID-19 vaccine approved for use in Japan− Approval for primary and booster immunization is based on efficacy and safety data from Japan and international clinical studies− Takeda is manufacturing Nuvaxovid at its Hikari facility and will begin distribution in Japan as soon as possiblehttps://finance.yahoo.com/news/takeda-announces-approval-nuvaxovid-covid-023300564.html